A Study of I-DXd in Combination With Atezolizumab With or Without Carboplatin as First-Line Induction or Maintenance in Subjects With Extensive Stage-Small Cell Lung Cancer (IDeate-Lung03)

NCT06362252 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

123

Enrollment

INDUSTRY

Sponsor class

Conditions

Extensive Stage-small Cell Lung Cancer

Interventions

DRUG: Ifinatamab deruxtecan
DRUG: Atezolizumab
DRUG: Carboplatin

Sponsor

Daiichi Sankyo

Collaborators

[object Object]